首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   150922篇
  免费   35747篇
  国内免费   1167篇
耳鼻咽喉   2902篇
儿科学   4123篇
妇产科学   3751篇
基础医学   10668篇
口腔科学   6135篇
临床医学   33037篇
内科学   33982篇
皮肤病学   3922篇
神经病学   17556篇
特种医学   5406篇
外国民族医学   57篇
外科学   24374篇
综合类   1329篇
现状与发展   40篇
一般理论   70篇
预防医学   19843篇
眼科学   3338篇
药学   5128篇
中国医学   40篇
肿瘤学   12135篇
  2024年   559篇
  2023年   5206篇
  2022年   1406篇
  2021年   3686篇
  2020年   5860篇
  2019年   2991篇
  2018年   7918篇
  2017年   8078篇
  2016年   8714篇
  2015年   8857篇
  2014年   11682篇
  2013年   14038篇
  2012年   6600篇
  2011年   6453篇
  2010年   8405篇
  2009年   10445篇
  2008年   6069篇
  2007年   5019篇
  2006年   6257篇
  2005年   4713篇
  2004年   3915篇
  2003年   3294篇
  2002年   3147篇
  2001年   3343篇
  2000年   2790篇
  1999年   3068篇
  1998年   2694篇
  1997年   2424篇
  1996年   2429篇
  1995年   2160篇
  1994年   1532篇
  1993年   1318篇
  1992年   1816篇
  1991年   1738篇
  1990年   1538篇
  1989年   1533篇
  1988年   1508篇
  1987年   1258篇
  1986年   1216篇
  1985年   1137篇
  1984年   957篇
  1983年   879篇
  1982年   610篇
  1981年   556篇
  1979年   731篇
  1978年   643篇
  1977年   557篇
  1976年   501篇
  1974年   516篇
  1973年   490篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.

Background

In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).

Methods

This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.

Results

The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.

Conclusions

These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.

Plain Language Summary

  • Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
  • Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
  • Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
  • Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
  相似文献   
72.
73.
Microglia, the innate immune cells of the CNS, perform critical inflammatory and noninflammatory functions that maintain normal neural function. For example, microglia clear misfolded proteins, elaborate trophic factors, and regulate and terminate toxic inflammation. In Alzheimer’s disease (AD), however, beneficial microglial functions become impaired, accelerating synaptic and neuronal loss. Better understanding of the molecular mechanisms that contribute to microglial dysfunction is an important objective for identifying potential strategies to delay progression to AD. The inflammatory cyclooxygenase/prostaglandin E2 (COX/PGE2) pathway has been implicated in preclinical AD development, both in human epidemiology studies and in transgenic rodent models of AD. Here, we evaluated murine models that recapitulate microglial responses to Aβ peptides and determined that microglia-specific deletion of the gene encoding the PGE2 receptor EP2 restores microglial chemotaxis and Aβ clearance, suppresses toxic inflammation, increases cytoprotective insulin-like growth factor 1 (IGF1) signaling, and prevents synaptic injury and memory deficits. Our findings indicate that EP2 signaling suppresses beneficial microglia functions that falter during AD development and suggest that inhibition of the COX/PGE2/EP2 immune pathway has potential as a strategy to restore healthy microglial function and prevent progression to AD.  相似文献   
74.
75.
76.
77.
Gray platelet syndrome (GPS) is a rare (<1/1 000 000) and inherited platelet function disorder characterized by macrothrombocytopenia, α-granule deficiency, and hemorrhages. Bleeding intensity does not correlate with platelet count nor with functional test results. We hereby describe the perioperative bleeding prevention and management of a patient with GPS requiring multiple redo cardiac surgeries.  相似文献   
78.
79.
80.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号